Ascentage Pharma Group International (Ascentage Pharma) announced that six abstracts covering its three lead oncology assets—olverembatinib (HQP1351), lisaftoclax (APG-2575) and alrizomadlin (APG-115)—have been accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026. Three studies secured rapid oral presentation slots and three will be delivered as posters, underscoring continued momentum across haematologic and solid‐tumour pipelines.

Rapid oral presentations 1. Olverembatinib plus blinatumomab in relapsed/refractory Ph+ B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) or lymphoid blast-phase chronic myeloid leukaemia (CML-LBP) delivered complete responses in four of five patients with measurable residual disease; two of these achieved MRD-negativity. Safety remained manageable. 2. In a second-line chronic-phase CML study, olverembatinib recorded a 91.30% complete cytogenetic response and a 60.90% major molecular response at cycle 24 among 42 evaluable patients. Among the subgroup that had failed prior second-generation TKIs, CCyR reached 81.30% and MMR 50.00%, with favourable tolerability. 3. Alrizomadlin monotherapy or in combination with lisaftoclax in heavily pretreated paediatric solid tumours showed no dose-limiting toxicities. One refractory rhabdomyosarcoma patient achieved complete response; combination therapy produced a 30% objective response rate and 80% disease-control rate.

Poster presentations • SDH-deficient tumours: Olverembatinib generated a 23.10% partial response rate and 25.70-month median progression-free survival in SDH-deficient GIST; a 66.70% clinical-benefit rate and 8.25-month median PFS were noted in SDH-deficient paraganglioma. Preclinical work implicates inhibition of the p38-CD36 pathway in antitumour activity. • POLARIS-2 Phase III: A global, FDA and EMA-cleared study randomising chronic-phase CML patients (≥2 prior TKIs) 2:1 to olverembatinib or bosutinib; a single-arm T315I cohort is also included. Major molecular response by week 24 is the primary endpoint. • GLORA Phase III: A 440-patient, 18-country trial evaluating lisaftoclax plus a BTK inhibitor in previously treated CLL/SLL patients who have not achieved complete response after 12 months of BTKi monotherapy.

Outlook The breadth of ASCO 2026 presentations reinforces Ascentage Pharma’s late-stage pipeline depth, particularly for olverembatinib in chronic-phase CML and SDH-deficient tumours, and supports ongoing registrational studies for both olverembatinib and lisaftoclax. A Rule 18A.05 cautionary note emphasises that alrizomadlin may not ultimately achieve successful commercialisation.